One of the patients treated with ruxolitinib required a switch to baricitinib and an associated IL-1 blocker after a relapse of alveolar hemorrhage and ILD progression on a CT scan [6,27,34,47]. This evidence concerns the gene IL1B and interstitial lung disease.